At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 103 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Descriptive Comfort Study of Brinzolamide 1% / Brimonidine Tartrate 0.2% Fixed Combination Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension and Brimonidine Tartrate 0.2% Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 103 participants.
Detailed Summary
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate 0.2% Ophthalmic Solution in subjects with open-angle glaucoma and/or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartSep 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedSep 1, 2011
Enrollment StartSep 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.8 years ago
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensiondrug
Brinzolamide ophthalmic suspension, 1%drug
Brimonidine tartrate ophthalmic solution, 0.2%drug